Novo Nordisk: Growth Amidst Competition & Patent Cliff

Font: Financial Modeling Prep  • Jun 19, 2026

Novo Nordisk (NYSE) Navigates Competition and Patent Cliffs with Strategic Growth

• Novo Nordisk (NYSE) faces intense competition from Eli Lilly in the diabetes and obesity drug markets, alongside ongoing pricing pressures.
• Analyst sentiment is mixed, with Nordea upgrading NVO stock to "Buy" while Deutsche Bank maintains a "Hold" due to concerns over the ZEUS trial and a significant patent cliff in 2031.
• Despite challenges, Novo Nordisk secured a major regulatory win with Wegovy pill approval in the U.K. for chronic weight management and plans further expansion into the Chinese market.

Novo Nordisk (NYSE) is a global healthcare company focused on diabetes care and other serious chronic diseases like obesity. This pharmaceutical giant develops and markets pharmaceutical products, with its main competitor being Eli Lilly, especially in the growing markets for diabetes and weight-loss treatments. Novo Nordisk faces ongoing pressures from pricing and competition in the pharmaceutical industry.

Analyst firm Nordea has upgraded its rating for Novo Nordisk to "Buy" from "Hold," reflecting a positive outlook for the NVO stock. At the time, the stock price was $43.19. However, this contrasts with Deutsche Bank's view. Deutsche Bank maintains a "Hold" rating and a price target of DKK290, seeing limited upside for the pharmaceutical stock.

Deutsche Bank's caution stems from the upcoming ZEUS trial and a future patent cliff. A patent cliff is when a company's key drugs lose patent protection, allowing cheaper generic versions to enter the market. For Novo Nordisk, this patent expiration in 2031 affects drugs that generate around $30 billion in revenue, posing a significant challenge to future revenue growth.

Despite these concerns, Novo Nordisk has achieved a major regulatory win. As highlighted by Zacks, the company received U.K. approval for its Wegovy pill for chronic weight management. This is the first oral GLP-1 obesity therapy approved in Europe, offering patients a non-injectable option and a new growth path for the obesity drug market.

Furthermore, Novo Nordisk plans to file for approval of oral Wegovy in China very soon, as reported by Gurufocus. This strategic move aims to strengthen its position against Eli Lilly in the Chinese pharmaceutical market. While a key Wegovy patent expires in 2026, the company believes its large-scale manufacturing capabilities will provide a significant competitive edge.